LEUKEMIAS

Following positive data examining ABC008 for inclusion body myositis, a phase 1/2 trial has begun evaluating the agent in patients with T-cell large granular lymphocytic leukemia.

Experts explain the treatment goals for patients with MDS, and discusses the role of molecular testing in patients with MDS.

Dr Eytan M Stein breaks down how patients with MDS are risk-stratified, and how the clinical outcomes differ between risk groups.

Hagop M. Kantarjian, MD, discusses what experts should know regarding ponatinib and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

The question of the most optimal therapy for Philadelphia chromosome-positive chronic myeloid leukemia has come down to asciminib vs ponatinib.

Hetty Carraway, MD, describes how MDS differs from acute myeloid leukemia (AML), and the percentage of patients who progress to AML from MDS.

Eytan M. Stein, MD, provides an overview of myelodysplastic syndrome, including risk factors, symptoms, and diagnosis.

Nitin Jain, MD, explains the key takeaways from multiple discussions on acute lymphoblastic leukemia which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology.

Tyrosine kinase inhibitors now enjoy frontline approval, yet the role of interferon continues to be explored.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, reviews advances in leukemia treatment for Leukemia Awareness Month.

Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.

Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.

Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.

Eytan Stein, MD, presents the case of an 81-year-old patient with AML who is unfit for intensive induction therapy for discussion.

Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.

Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.

Eytan Stein, MD, reviews the available treatment options for patients with secondary AML or AML with myelodysplasia-related changes.

Hetty Carraway, MD, describes the criteria used to determine if a patient with newly-diagnosed acute myeloid leukemia is suitable for intensive induction therapy.

Eytan Stein, MD, provides an overview of the frontline treatment options currently available for acute myeloid leukemia.

Experts explain the goals of treatment for acute myeloid leukemia and the challenges presented.

Hetty Carraway, MD, discusses the process of diagnosing acute myeloid leukemia and its clinical subtypes.

The FDA has granted fast track designation and rare pediatric disease designation for WU-CART-007 as treatment for patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.

Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.

Courtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.

A review of the safety outcome data of venetoclax plus azacitidine from the VIALE-A trial.

Dr Courtney DiNardo details the dosing recommendations for venetoclax plus azacitidine and the importance of bone marrow assessments.

Dr Courtney DiNardo reviews the efficacy data from the VIALE-A trial and explains the rationale for combining venetoclax with azacitidine as a treatment option for patients with AML.

Courtney DiNardo, MD, describes how the treatment options for patients with newly diagnosed acute myeloid leukemia differs for patients under and over 60 years of age.

Quizartinib with standard induction and consolidation chemotherapy followed by continued quizartinib monotherapy treatment led to significant improvement in overall survival in patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.

The FDA has granted approval to azacitidine for the treatment of pediatric patients with newly diagnosed juvenile myelomonocytic leukemia following positive phase 2 research.